Multiplicity of Advanced T Category–Tumors Is a Risk Factor for Survival in Patients with Colorectal Carcinoma

Hye Eun Park¹ · Seungyeon Yoo¹ · Jeong Mo Bae¹ · Seorin Jeong² · Nam-Yun Cho² · Gyeong Hoon Kang¹,²
¹Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul; ²Laboratory of Epigenetics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea

Background: Previous studies on synchronous colorectal carcinoma (SCRC) have reported inconsistent results about its clinicopathologic and molecular features and prognostic significance.

Methods: Forty-six patients with multiple advanced tumors (T2 or higher category) who did not receive neoadjuvant chemotherapy and/or radiotherapy and who are not associated with familial adenomatous polyposis were selected and 99 tumors from them were subjected to clinicopathologic and molecular analysis. Ninety-two cases of solitary colorectal carcinoma (CRC) were selected as a control considering the distributions of types of surgeries performed on patients with SCRC and T categories of individual tumors from SCRC. Results: SCRC with multiple advanced tumors was significantly associated with more frequent nodal metastasis (p = .003) and distant metastasis (p = .001) than solitary CRC. KRAS mutation, microsatellite instability, and CpG island methylator phenotype statuses were not different between SCRC and solitary CRC groups. In univariate survival analysis, overall and recurrence-free survival were significantly lower in patients with SCRC than in patients with solitary CRC, even after adjusting for the extensiveness of surgical procedure, adjvant chemotherapy, or staging. Multivariate Cox regression analysis revealed that tumor multiplicity was an independent prognostic factor for overall survival (hazard ratio, 4.618; 95% confidence interval, 2.126 to 10.030; p < .001), but not for recurrence-free survival (p = .151).

Conclusions: Findings suggested that multiplicity of advanced T category–tumors might be associated with an increased risk of nodal metastasis and a risk factor for poor survival, which raises a concern about the guideline of American Joint Committee on Cancer’s tumor-node-metastasis staging that T staging of an index tumor determines T staging of SCRC.

Key Words: Synchronous colorectal carcinoma; Multiple colorectal carcinoma; Clinical outcome; T category

Colorectal carcinoma (CRC) is the third most common cancer in men and the second most common in women. CRC has been reported to occur more commonly in the western countries, but over the past few decades, the incidence of CRC has increased in many Asian countries including South Korea, with about 610,000 Asian patients newly diagnosed in 2012.¹ Synchronous CRC (SCRC) refers to more than one CRC detected in a single patient at the time of diagnosis. Unlike what is expected, little is known about the clinicopathologic features of SCRC. With a handful of previous studies addressing the issue, the only consensus seems to be the male predominance; most of the previous studies reported that SCRC was observed more frequently in men.²⁻⁶ The reported incidence of SCRCs varies from 1.1% to 8.1%,³⁻⁷⁻¹⁵ with the narrower range of 3.1% to 3.9% in three large-scale studies performed on a population larger than 10,000 patients.³⁻¹²⁻¹³ While some studies concluded that the average age at diagnosis was higher in patients with SCRC than in patients with solitary CRC,¹⁰⁻¹¹⁻¹⁶ others failed to demonstrate a significant difference between them.¹²⁻¹³⁻¹⁷ Some studies reported that SCRC preferentially affects the distal colon,²⁻⁵⁻¹⁰⁻¹⁶⁻¹⁷⁻¹⁸ but others, including large-scale studies, concluded that the proximal colon was more frequently involved by SCRC.²¹⁻²²

Research has mainly focused on single factors such as microsatellite instability (MSI) for the underlying molecular mechanisms of SCRC. Some studies have reported that MSI-high (MSI-H) phenotype was more common in SCRC than in solitary CRC and the incidence of MSI-H phenotype was up to 30% in SCRC.²³⁻²⁵ In particular, Nosho et al.²⁶ found that not only MSI-H phenotype but also BRAF mutation and CpG island methylator phenotype (CIMP)-high (CIMP-H) phenotype were more common in SCRC than in solitary CRC, suggesting that SCRC may arise through the serrated neoplasia pathway. A similar finding has been reported by Gonzalo et al.²⁷ who found that CIMP-H was more frequent in SCRC than in solitary CRC and...
suggested a close association between tumor multiplicity and CIMP-H phenotype. However, one study reported that MSI occurs only in 10% of SCRCs.28 Besides MSI, long interspersed nuclear element-1 (LINE-1) hypomethylation in colonic epithelial cells has been suggested to be a possible risk factor for the occurrence of metachronous or SCRC based on finding that LINE-1 methylation of non-neoplastic colonic epithelial cells was lower in SCRC than in solitary CRC.29 Some studies found that KRAS and TP53 may show discordant mutation statuses between individual tumors of SCRCs,30,31 but correlations between SCRC and various clinicopathological or molecular parameters still remain unclear.

It seems plausible that a patient with multiple tumors at the time of diagnosis would show poorer prognosis than one with a solitary tumor. Strikingly, this has not been proved with the sufficient level of confidence in CRC, which is the reason that the current TNM staging of CRC does not reflect tumor multiplicity unlike other cancers such as intrahepatic cholangiocarcinoma.32 In fact, the prognostic effect of tumor multiplicity at the time of diagnosis has been inconsistent among studies; with only a few studies reporting significantly worse prognosis,26,33 many failed to demonstrate significant differences in survival between patients with solitary CRC and SCRC and some researchers even concluded that SCRC was associated with favorable prognosis.10,22 Therefore, the current TNM staging guideline for SCRC advises that the lesion with the most advanced pathologic staging is designated to be an index lesion and it is assumed that the survival of the patients with SCRC follows the stage of the index lesions.3,22 In this scheme, patients with SCRC with the index lesion of pT3 category would show similar survival to those with solitary pT3 CRC.

The purpose of the current study is to address all the inconsistency and to draw clearer conclusion on the prognostic effect of the tumor multiplicity at the time of diagnosis. To do so, we identified a group of patients with SCRCs with advanced T categories, examined their clinicopathologic and molecular features and compared their survival to those with the comparable group of patients with solitary CRC.

MATERIALS AND METHODS

Tissue collection

Two thousand eight hundred thirty-four CRC patients who underwent surgery at Seoul National University Hospital, Seoul, Korea, from January 2007 to December 2010 were reviewed. Among them, 2,701 were solitary CRC patients and 133 were diagnosed as SCRC. From the 133 patients, we excluded patients with familial adenomatous polyposis (FAP) (n = 3) and those who received neoadjuvant chemo- and/or radiotherapy (n = 8). In order to focus on patients with advanced stages, we further excluded patients with intramucosal carcinoma (n = 37) and T1-category lesions (n = 39). As a result, 46 cases with multiple advanced tumors (T2 or higher category) were selected for this study (Fig. 1). Of the 46 patients, 16 underwent extensive surgery including total colectomy and subtotal colectomy, and 30 had a relatively simple procedure (8 cases of anterior resection, 14 cases of ultra-low or low anterior resection, 4 cases of right or left hemicolectomy, and 4 cases of extended right hemicolectomy). Considering the distributions of pT categories of individual tumors and types of surgeries performed on patients with SCRC, we selected 92 cases of solitary CRC with similar distributions of pT categories (Table 1) and types of surgeries (35 cases of anterior resection, 31 cases of low anterior resection, 12 cases of right or left hemicolectomy, and 14 cases of extended right hemicolectomy). However, we could not retrieve patients with solitary CRC who received extensive surgery. This study was approved by the Institutional Review Board (IRB No. 1101-007-345). IRB exempted the informed consent due to the retrospective nature of the study.

Clinicopathologic data

Clinical and histopathologic data from the 46 patients with SCRC (99 tumors) and 92 patients with solitary CRC (92 tumors) were collected through the electronic medical record and a microscopic examination. The parameters of the clinicopathologic data included patient age, sex, overall survival (OS), recurrence-free survival (RFS), tumor location, tumor multiplicity, American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) tumor-node-metastasis (TNM) category, tumor differentiation, lymphovascular invasion, and perineural invasion.

KRAS mutation and MSI analysis

Through histological examination, representative tumor portions were marked and then subjected to manual microdissection. The dissected tissues were collected into microtubes containing lysis buffer and proteinase K and were incubated at 55°C for up to 2 days. DNA from paraffin-embedded tissues was extracted, and polymerase chain reaction was performed. Mutations in KRAS codons 12 and 13 were analyzed in each case using direct sequencing. The MSI status of each tumor was determined through the evaluation of five microsatellite markers (BAT25, BAT26, D2S123, D5S346, and D17S250) as standardized by the National Cancer Institute. MSI-H status was defined as when tumor DNA
had altered alleles compared to normal DNA in two or more markers. MSI-low status was defined as when tumor DNA had altered allele compared to normal DNA in one marker. Microsatellite-stable was defined as when no altered allele was present in tumor DNA. We performed immunohistochemistry (IHC) for DNA mismatch repair proteins (MLH1 and MSH2) to assess MSI status for tumors that were not evaluated for MSI status using polymerase chain reaction-coupled capillary electrophoresis (50 individual tumors from SCRCs and 3 solitary CRCs). IHC was performed using antibodies against MLH1 (Ventana Medical Systems, Tucson, AZ, USA), MSH2 (Invitrogen, Camarillo, CA, USA) and automated immunostainers (Ventana BenchMark XT for MLH1; Bond-III, Leica Biosystems, Newcastle-upon-Tyne, UK for MSH2).

Analysis of CIMP

The CIMP status of individual tumors was analyzed using a real-time methylation-specific quantitative polymerase chain reaction method (MethyLight) and eight CIMP-specific markers (CACNA1G, CDKN2A, CRABP1, IGF2, MLH1, NEUROG1, RUNX3, and SOCS1). We classified CRCs into CIMP-0 (no methylated marker), CIMP-low (1–4 methylated markers), and CIMP-H (5 or more methylated markers).

Statistical analysis

In this study, statistical analysis was performed using SPSS ver. 23 (IBM Corp., Armonk, NY, USA). Comparison between categorical variables was conducted with the chi-square test or Fisher exact test. Survival analysis using OS and RFS data was performed using the Kaplan-Meier method with the log-rank test. Hazard ratios (HRs) were calculated using the Cox proportional hazard model. All variables that were associated with OS with a p < .10 were entered into the model. These variables were reduced by backward elimination. All p-values were two-sided and p-values of < .05 were considered to be statistically significant.

RESULTS

Clinicopathologic features

The detailed clinicopathologic features are summarized in Table 1 and Fig. 2. SCRC with multiple advanced tumors was associated with more frequent nodal metastasis (p = .003) and advanced TNM category (p = .003). SCRC exhibited a tendency toward male predominance with marginal significance (p = .050). Metachronous metastasis was significantly more frequent in SCRCs with multiple advanced tumors than in solitary CRCs (p = .050). However, there were no significant differences in terms of lymphatic and vascular invasion between two groups. In addition, KRAS mutation and MSI status did not show any significant difference between the two groups. In CIMP analysis for SCRC, CIMP-H phenotype was observed in four of 46 patients (8.7%), which was quite lower compared with results of previous studies (35% in Nosho et al.’s study26 and 66.6% in Gonzalo et al.’s study27). However, the frequency of CIMP-H in terms of individual tumors was 5.1% (5 of 99 tumors) which was not different from the frequency of CIMP-H in solitary CRCs (6.5%) of the
present study and those of previous Korean CRC studies.\(^{34,35}\) Nodal and distant metastasis showed significant differences between SCRC and solitary CRC when we restricted comparative analyses to CRC cases with non-extensive surgery or cases with R0 surgery (Table 2).

### Prognostic implication of tumor multiplicity in CRCs

In order to examine the prognostic effect of tumor multiplicity per se, we sought to focus on subgroups where compounding variables were adjusted. Firstly, we performed Kaplan-Meier survival analysis on patients who had no metastasis at the time of diagnosis and hence underwent curative surgery (85 patients with solitary CRC and 34 patients with SCRC). As a result, SCRC patients with multiple advanced tumors showed worse OS and RFS than the respective ones of patients with solitary CRC (Fig. 3A, B). Since it cannot be excluded a possibility that the extensiveness of surgery itself might affect the survival of patients with SCRC, survival analysis was conducted in 85 solitary CRC and 22 SCRC patients with exclusion of patients who underwent the extensive surgical procedures such as total colectomy and subtotal colectomy, which revealed significant associations between SCRC and poor OS or RFS (Fig. 3C, D). When we further excluded patients who did not receive adjuvant chemotherapy to adjust for the effect of adjuvant chemotherapy, univariate survival analysis in 36 patients with solitary CRC and 13 patients with SCRC revealed that the prognosis of SCRC with multiple advanced tumors tended to be worse than that of solitary CRC patients (Fig. 3E, F). To validate these results, we selected 24 SCRC cases with an index tumor of T3 category and recruited another independent set of patients with solitary CRC of T3 category (n = 120) on the criteria of R0 surgery and adjuvant chemotherapy. Because SCRC cases were composed of nine N0, seven N1, and eight N2 cases, 45 solitary CRC cases of N0 category, 35 of N1 category, and 40 of N2 category were recruited.

---

**Table 1. Clinicopathologic and molecular characteristics of CRCs according to tumor multiplicity**

| Variable | Solitary CRCs (92 patients, 92 tumors) | Synchronous CRCs (46 patients, 99 tumors) | p-value |
|----------|--------------------------------------|------------------------------------------|---------|
| Age (yr) | 63.5 (33–82) | 66.0 (43–88) | .087 |
| Sex      |                                      |                                          | .050    |
| Male     | 59 (64.1) | 37 (80.4) |          |
| Female   | 33 (35.9) | 9 (19.6) |          |
| Location |                                      |                                          | .247    |
| Proximal | 18 (19.6) | 29 (29.3) |          |
| Distal   | 48 (52.2) | 42 (42.4) |          |
| Rectum   | 26 (28.3) | 28 (28.3) |          |
| Gross type |                                    |                                          | .114    |
| Polypod  | 11 (12.0) | 22 (22.2) |          |
| Ulcerofungating | 61 (66.3) | 53 (53.5) |          |
| Ulceroinfiltrative | 20 (21.7) | 24 (24.2) |          |
| T category |                                    |                                          | .548    |
| T2       | 12 (13.0) | 18 (18.2) |          |
| T3       | 73 (79.3) | 72 (72.7) |          |
| T4       | 7 (7.6)   | 9 (9.1)   |          |
| N category |                                    |                                          | .003    |
| N0       | 49 (53.3) | 12 (26.1) |          |
| N1, N2   | 43 (46.7) | 34 (73.9) |          |
| M category |                                    |                                          | .001    |
| M0       | 73 (79.3) | 23 (50.0) |          |
| Synchronous M1 | 7 (7.6) | 12 (26.1) |          |
| Metachronous M1 | 12 (13.0) | 23 (23.9) |          |
| Stage    |                                      |                                          | .003    |
| I        | 9 (9.8)   | 1 (2.2)   |          |
| II       | 40 (43.5) | 11 (23.9) |          |
| III      | 36 (39.1) | 22 (47.8) |          |
| IV       | 7 (7.6)   | 12 (26.1) |          |
| Surgery  |                                      |                                          | <.001   |
| Simple   | 92        | 30 (65.2) |          |
| Extensive | 0        | 16 (34.8) |          |
| Chemotherapy |                                  |                                          | 1.000   |
| Treated  | 80 (87.0) | 40 (87.0) |          |
| Non-treated | 12 (13.0) | 6 (13.0) |          |
| Differentiation |                                |                                          | .722a   |
| Well     | 9 (9.8)   | 9 (9.1)   |          |
| Moderately | 78 (84.8) | 87 (87.9) |          |
| Poorly   | 5 (5.4)   | 3 (3.0)   |          |
| Lymphatic invasion |                          |                                          | .068    |
| Absent   | 73 (79.3) | 67 (67.7) |          |
| Present  | 19 (20.7) | 32 (32.3) |          |
| Venous invasion |                        |                                          | .086    |
| Absent   | 86 (93.5) | 85 (85.9) |          |
| Present  | 6 (6.5)   | 14 (14.1) |          |
| Perineural invasion |                           |                                          | .986    |
| Absent   | 80 (87.0) | 86 (86.9) |          |
| Present  | 12 (13.0) | 14 (13.1) |          |
| MSI      |                                      |                                          | 0.740a  |
| MSS/MSI-low | 87 (94.6) | 95 (96.0) |          |

(Continued)
Kaplan-Meier survival analysis showed that patients with SCRC still had worse OS compared with patients with solitary CRC group that matched T and N category, but not for RFS (Fig. 3G, H). In multivariate Cox regression analysis, tumor multiplicity was found to be an independent prognostic factor for OS (HR, 4.618; 95% confidence interval, 2.126 to 10.030; p < .001), but not for RFS (p = .151) (Tables 3, 4).

**DISCUSSION**

In this study, we investigated the clinicopathologic and molecular characteristics of SCRC as well as the prognostic implication of the tumor multiplicity at the time of diagnosis. The reported incidence of SCRC in the literature varies from 1.1% to 8.1%. This variance might be attributable to the difference in the definition of SCRC; whether FAP or intramucosal carcinoma is included or not in the definition of SCRC can make a significant difference. In this study, we excluded SCRC associated with FAP (n = 3). The incidence of SCRC was 4.6% (n = 130) when intramucosal carcinomas were included and 3.2% (n = 91) when excluded, in line with the previous studies. Of these patients (n = 91), we excluded those patients who received neoadjuvant chemotheray (n = 6) or T1-category lesion (n = 39). We only selected SCRCs in which all the individual tumors were of pT2 or higher category and resultantly, 46 patients were included in the present study.

The median age at diagnosis of SCRC with multiple advanced tumors was higher than that of solitary CRC, but the difference did not reach a statistical significance in this study. Several studies have reported that the mean age of patients with SCRC is significantly higher than that of patients with solitary CRC. However, in Oya et al.'s study, age difference failed to reach the statistical significance, and Latournerie et al. conducted a large-scale study to discover that there was no significant difference. Regarding sex distribution, previous studies reported that SCRC is more common in men, but this study confirmed this tendency only with the marginal significance. Previous studies have reported inconsistent results on the sidedness of SCRC. Finan et al. reported that SCRC is more common in the distal part of colon, the same with the solitary CRC in general, but Lam et al. showed that SCRC more commonly affects the proximal colon than solitary CRC does. In the present study, SCRC showed a ten-
Synchronous Colorectal Carcinoma

In line with several previous studies which showed that the proportion of advanced stage is higher in SCRC than in solitary CRC, we discovered that SCRC cases tended to be more advanced than solitary cases. Lymphatic and venous invasions tended to be more frequent in individual tumors of SCRC than in solitary CRC. Although our findings indicated that nodal metastasis was significantly more common in SCRC with multiple advanced tumors than in solitary CRC, a concern is that selection of solitary CRC might be biased toward collection of solitary CRC with less frequent nodal metastasis. To exclude such a possibility, we analyzed the frequency of nodal metastasis in 593 cases of solitary T3 CRC. The frequency of N0 was significantly higher in solitary T3 CRC than in SCRC with an index tumor of T3 category (45.5% vs. 26.3%, p = .027). This finding suggests that multiplicity of advanced T category–tumors might be a risk factor for nodal metastasis.

Molecular analysis performed in this study revealed that the prevalence of MSI and KRAS mutation in the SCRC were not different from the respective ones of the solitary CRC. Out of the 99 individual tumors from 46 SCRC patients, only four tumors from two patients were MSI-H. The analysis of CIMP status for these tumors showed that these MSI-H tumors were negative for MLH1 methylation and not CIMP-H, which suggests the possibility that these SCRC patients with multiple MSI-H tumors might be patients with Lynch syndrome. In fact, both of these patients had first-degree relatives with CRC as well as SCRC with MSI-H phenotype, and could be diagnosed as hereditary non-polyposis colon cancer. However, in previous studies, exploration on MSI status of SCRC showed a higher proportion of MSI-H phenotype in SCRC than in solitary CRC. Nosho et al. found that SCRC was more likely to be BRAF-mutated, CIMP-H and MSI-H, suggesting that MSI-H phenotype in SCRC is likely to be sporadic rather than hereditary. Such a discrepancy between previous studies and the present study might be attributable to the fact that we excluded tumors of Tis or T1 category or the fact

Table 2. Differences in clinicopathologic characteristics according to subgroup analysis

| Variable | Total cases of CRC | Solitary CRC (n=92) | SCRC (n=46) | CRC cases with R0 resection | Solitary CRC (n=85) | SCRC (n=34) | CRC cases with non-extensive surgery | Solitary CRC (n=92) | SCRC (n=30) |
|----------|-------------------|-------------------|-----------|-----------------------------|-------------------|-----------|-----------------------------------|-------------------|-----------|
| Age (yr) | 63.5 (33–82)      | 66.0 (43–88)      | 63.0 (33–82) | 66.0 (48–79)                | 63.5 (33–82)      | 66.0 (43–88) |                                   |                   |           |
| p-value  | .087              | .150              | .168      |                             |                   |           |                                   |                   |           |
| Sex      |                   |                   |           |                             |                   |           |                                   |                   |           |
| Male     | 59 (64.1)         | 37 (80.4)         | 56 (65.9) | 25 (73.5)                   | 59 (64.1)         | 24 (80.0) |                                   |                   |           |
| Female   | 33 (35.9)         | 9 (19.6)          | 29 (34.1) | 9 (26.5)                    | 33 (35.9)         | 6 (20.0)  |                                   |                   |           |
| p-value  | .050              | .419              | .106     |                             |                   |           |                                   |                   |           |
| T category |               |                   |           |                             |                   |           |                                   |                   |           |
| T2       | 12 (13.0)         | 18 (18.2)         | 12 (14.1) | 13 (17.8)                   | 12 (13.0)         | 13 (20.3) |                                   |                   |           |
| T3       | 73 (79.3)         | 72 (72.7)         | 68 (80.0) | 52 (71.2)                   | 73 (79.3)         | 42 (65.6) |                                   |                   |           |
| T4       | 7 (7.6)           | 9 (9.1)           | 5 (5.9)   | 8 (11.0)                    | 7 (7.6)           | 9 (14.1)  |                                   |                   |           |
| p-value  | .548              | .374              | .154     |                             |                   |           |                                   |                   |           |
| N category |               |                   |           |                             |                   |           |                                   |                   |           |
| N0       | 49 (53.3)         | 12 (26.1)         | 49 (57.6) | 12 (35.3)                   | 49 (53.3)         | 8 (26.7)  |                                   |                   |           |
| N1, N2   | 43 (46.7)         | 34 (73.9)         | 36 (42.4) | 22 (64.7)                   | 43 (46.7)         | 22 (73.3) |                                   |                   |           |
| p-value  | .003              | .028              | .011     |                             |                   |           |                                   |                   |           |
| M category |               |                   |           |                             |                   |           |                                   |                   |           |
| M0       | 73 (79.3)         | 23 (50.0)         | 73 (85.9) | 23 (67.6)                   | 73 (79.3)         | 14 (46.7) |                                   |                   |           |
| Synchronous M1 | 7 (7.6)      | 12 (26.1)         | -        | -                           | 7 (7.6)           | 8 (26.7)  |                                   |                   |           |
| Metachronous M1 | 12 (13.0) | 11 (23.9)         | 12 (14.1) | 11 (32.4)                   | 12 (13.0)         | 8 (26.7)  |                                   |                   |           |
| p-value  | .001              | .023              | .002     |                             |                   |           |                                   |                   |           |
| Lymphatic invasion |          |                   |           |                             |                   |           |                                   |                   |           |
| Absent   | 73 (79.3)         | 67 (67.7)         | 69 (81.2) | 53 (72.6)                   | 73 (79.3)         | 37 (57.8) |                                   |                   |           |
| Present  | 19 (20.7)         | 32 (32.3)         | 16 (18.8) | 20 (27.4)                   | 19 (20.7)         | 27 (42.2) |                                   |                   |           |
| p-value  | .068              | .200              | .004     |                             |                   |           |                                   |                   |           |
| Venous invasion |            |                   |           |                             |                   |           |                                   |                   |           |
| Absent   | 86 (93.5)         | 85 (85.9)         | 81 (95.3) | 65 (89.0)                   | 86 (93.5)         | 55 (85.9) |                                   |                   |           |
| Present  | 6 (6.5)           | 14 (14.1)         | 4 (4.7)   | 8 (11.0)                    | 6 (6.5)           | 9 (14.1)  |                                   |                   |           |
| p-value  | .086              | .139              | .116     |                             |                   |           |                                   |                   |           |

Values are presented as median (range) or number (%).
that the frequency of CIMP-H phenotype is lower in CRCs from Korean patients than those from western people.36

Most of the previous studies reported that the survival of the patients with SCRC was not significantly different from that of patients with solitary CRC and only depended on the pathologic staging of the index cancer.22 Even Hu et al.10 suggested that patients with SCRC might have survival benefit. Only a few studies have discovered that patients with SCRC had worse prognosis than that of patients with solitary CRC.26,33 It should be pointed out that previous studies which reported no difference in survival between SCRC and solitary CRC were conducted on a population of SCRC in which SCRC with Tis or T1 tumor as a non-index tumor comprise approximately 46% and 30% of the study cases, respectively.16,22 In accordance with the hypothesis that patients with multiple advanced tumors would indeed have more tumor burden, we only selected SCRC cases in which all the individual tumors were of T2 or higher categories. Kaplan-Meier survival analysis showed that SCRC patients with multi-
ple advanced tumors had worse survival than that of patients with solitary CRC. We performed a subgroup analysis in order to adjust for the effect of adjuvant chemotherapy, extensive surgical procedure such as total colectomy or subtotal colectomy, T and N categories, and discovered that tumor multiplicity was an independent prognostic factor for OS in multivariate analysis. The reason why SCRC patients with multiple advanced tumors pursue worse clinical outcome than patients with solitary CRC is related to the fact that SCRC was associated with more frequent nodal metastasis and metachronous metastasis.

In conclusion, we selected SCRC with all the individual tumors of T2 or higher category and compared various characteristics between SCRC and solitary CRC of similar T category–distribution. We found that SCRC was featured with higher incidence of nodal metastasis and metachronous metastasis and shortened OS time compared with solitary CRC. Based on the finding that multiplicity of advanced T category–tumors was an independent prognostic parameter heralding poor overall survival, the current staging of SCRC with multiple advanced tumors according to the tumor-node-metastasis guideline of AJCC that an index tumor of advanced T category determines the T category of SCRC, is likely to evaluate better than actual prognosis. More studies would be needed to validate this finding and discover the underlying mechanism of it.

ORCID

Hye Eun Park: https://orcid.org/0000-0003-1048-2827
Jeong Mo Bae: https://orcid.org/0000-0003-0462-3072
Gyeong Hoon Kang: https://orcid.org/0000-0003-2380-6675

Table 3. Univariate and multivariate Cox analysis for overall survival (n=119)

| Variable                        | Univariate | p-value | Multivariate | p-value |
|---------------------------------|------------|---------|--------------|---------|
| Age (≥ 65 yr/< 65 yr)           | 4.089(1.728–9.673) | .001 | 4.041(1.703–9.587) | .002 |
| Sex (male/female)               | 1.051(0.472–2.347) | .902 | -             | -     |
| Multiplicity (synchronous/solitary) | 5.075(2.350–10.960) | <.001 | 4.618(2.126–10.030) | <.001 |
| T category (T3, 4/T2)           | 3.487(1.473–25.709) | .220 | -             | -     |
| N category (N1, 2/N0)           | 3.617(1.528–8.564) | .003 | 3.072(1.291–7.309) | .011 |
| Vascular invasion (present/absent) | 2.373(0.897–6.273) | .082 | -             | .159 |
| Lymphatic invasion (present/absent) | 2.836(1.326–6.065) | .007 | -             | .122 |
| Perineural invasion (present/absent) | 1.617(0.612–4.270) | .333 | -             | -     |
| Tumor location (including right colon/left colon only) | 0.907(0.397–2.072) | .817 | -             | -     |
| Chemotherapy (treated/not-treated) | 1.088(0.376–3.147) | .876 | -             | -     |
| Surgery (extensive/simple)      | 1.832(0.636–5.314) | .262 | -             | -     |
| MSI (MSI-H/MSS, MSI-L)          | 0.045(0.009–33.308) | .357 | -             | -     |
| KRAS (mutant/wild type)         | 2.337(1.049–5.204) | .038 | -             | -     |

HR, hazard ratio; MSI, microsatellite instability; MSI-H, MSI-high; MSS, microsatellite-stable; MSI-L, MSI-low.

Table 4. Univariate and multivariate Cox analysis for recurrence-free survival (n = 119)

| Variable                        | Univariate | p-value | Multivariate | p-value |
|---------------------------------|------------|---------|--------------|---------|
| Age (≥ 65 yr/< 65 yr)           | 1.803(0.791–4.114) | .161 | 2.163(0.905–5.171) | .083 |
| Sex (male/female)               | 1.672(0.733–3.815) | .222 | -             | -     |
| Multiplicity (synchronous/solitary) | 2.939(1.294–6.674) | .010 | -             | .151 |
| T category (T3, 4/T2)           | 2.993(1.403–22.224) | .284 | -             | -     |
| N category (N1, 2/N0)           | 4.378(1.623–11.805) | .004 | 3.943(1.457–10.670) | .007 |
| Vascular invasion (present/absent) | 3.658(1.440–9.294) | .006 | 4.114(1.527–11.081) | .005 |
| Lymphatic invasion (present/absent) | 3.096(1.365–7.025) | .007 | -             | .225 |
| Perineural invasion (present/absent) | 2.417(0.952–6.136) | .063 | -             | -     |
| Tumor location (including right colon/left colon only) | 1.370(0.509–3.690) | .534 | -             | -     |
| Chemotherapy (treated/not-treated) | 0.555(0.130–2.369) | .427 | -             | -     |
| Surgery (extensive/simple)      | 1.533(0.456–5.169) | .489 | -             | -     |
| MSI (MSI-H/MSS, MSI-L)          | 0.045(0.009–63.182) | .401 | -             | -     |
| KRAS (mutant/wild type)         | 1.776(1.078–2.945) | .179 | -             | -     |

HR, hazard ratio; MSI, microsatellite instability; MSI-H, MSI-high; MSS, microsatellite-stable; MSI-L, MSI-low.
Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

Acknowledgments

This work was supported by a grant from the National Research Foundation (NRF) funded by the Korean Ministry of Science, ICT and Future Planning (2016M3A9B6026921) and a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute funded by the Korean Ministry of Health and Welfare (HI14C1277).

REFERENCES

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-86.
2. Ghiringhelli F, Hennequin A, Drouillard A, Lepage C, Faivre J, Bouvier AM. Epidemiology and prognosis of synchronous and metachronous colon cancer metastases: a French population-based study. Dig Liver Dis 2014; 46: 854-8.
3. Kaibara N, Koga S, Jinnai D. Synchronous and metachronous malignancies of the colon and rectum in Japan with special reference to a coexisting early cancer. Cancer 1984; 54: 1870-4.
4. Lam AK, Chan SS, Leung M. Synchronous colorectal cancer: clinical, pathological and molecular implications. World J Gastroenterol 2014; 20: 6815-20.
5. Oya M, Takahashi S, Okuyama T, Yamaguchi M, Ueda Y. Synchronous colorectal carcinoma: clinico-pathological features and prognosis. Jpn J Clin Oncol 2003; 33: 38-43.
6. Yang J, Peng JY, Chen W. Synchronous colorectal cancers: a distinct subset arising from multiple sessile serrated adenomas and associated with high levels of microsatellite instability and favorable prognosis. Am J Surg Pathol 2013; 37: 1660-70.
7. Kimura T, Iwagaki H, Fuchimoto S, Hizuta A, Orita K. Synchronous colorectal carcinomas. Hepatogastroenterology 1994; 41: 409-12.
8. Latourmerie M, Joost V, Cottet V, Lepage C, Faivre J, Bouvier AM. Epidemiology and prognosis of synchronous colorectal cancers. Br J Surg 2008; 95: 1528-33.
9. Mulder SA, Kranse R, Dambuis RA, et al. Prevalence and prognosis of synchronous colorectal cancer: a Dutch population-based study. Cancer Epidemiol 2011; 35: 442-7.
10. Ueno M, Muto T, Oya M, Ota H, Azekura K, Yamaguchi T. Multiple primary cancer: an experience at the Cancer Institute Hospital with special reference to colorectal cancer. Int J Clin Oncol 2003; 8: 162-7.
11. Wang HZ, Huang XF, Wang Y, Ji JF, Gu J. Clinical features, diagnosis, treatment and prognosis of multiple primary colorectal carcinoma. World J Gastroenterol 2004; 10: 2136-9.
12. Kato T, Alonso S, Muto Y, et al. Clinical characteristics of synchronous colorectal cancers in Japan. World J Surg Oncol 2016; 14: 272.
13. Chen HS, Sheen-Chen SM. Synchronous and ‘early’ metachronous colorectal adenocarcinoma: analysis of prognosis and current trends. Dis Colon Rectum 2000; 43: 1093-9.
14. Finan PJ, Ritchie JK, Hawley PR. Synchronous and ‘early’ metachronous carcinomas of the colon and rectum. Br J Surg 1987; 74: 945-8.
15. Kim YJ, Kim NK, Lee KY, Sohn SK, Min JS. Clinicopathological characteristics of multiple primary colorectal cancer. J Korean Soc Coloproctol 2002; 18: 343-8.
16. Kang KG, Kim DH, Kim CH, Lee SH, Choi YJ. Clinical characteristics of synchronous multiple colorectal cancer. J Korean Soc Coloproctol 2006; 22: 418-23.
17. Welch JP. Multiple colorectal tumors: an appraisal of natural history and therapeutic options. Am J Surg 1981; 142: 274-80.
18. Pedroni M, Tamassia MG, Porcesepe A, et al. Microsatellite instability in multiple colorectal tumors. Int J Cancer 1999; 81: 1-5.
19. Norrie MW, Hawkins NJ, Todd AV, Meagher AP, O’Connor TW, Ward RL. The role of hMLH1 methylation in the development of synchronous sporadic colorectal carcinomas. Dis Colon Rectum 2002; 45: 674-80.
20. Dykes SL, Qui H, Rothenberger DA, García-Aguilar J. Evidence of a preferred molecular pathway in patients with synchronous colorectal cancer. Cancer 2003; 98: 48-54.
21. Nosho K, Kure S, Irahara N, et al. A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancer. Jpn J Cancer Res 2003; 94: 591-6.
colorectal cancers. Gastroenterology 2009; 137: 1609-20.e1-3.
27. Gonzalo V, Lozano JJ, Alonso-Espinaco V, et al. Multiple sporadic colorectal cancers display a unique methylation phenotype. PLoS One 2014; 9: e91033.
28. Brueckl WM, Limmert T, Brabletz T, et al. Mismatch repair deficiency in sporadic synchronous colorectal cancer. Anticancer Res 2000; 20: 4727-32.
29. Kamiyama H, Suzuki K, Maeda T, et al. DNA demethylation in normal colon tissue predicts predisposition to multiple cancers. Oncogene 2012; 31: 5029-37.
30. Eguchi K, Yao T, Konomoto T, Hayashi K, Fujishima M, Tsuneyoshi M. Discordance of p53 mutations of synchronous colorectal carcinomas. Mod Pathol 2000; 13: 131-9.
31. Giannini R, Lupi C, Loupakis F, et al. KRAS and BRAF genotyping of synchronous colorectal carcinomas. Oncol Lett 2014; 7: 1532-6.
32. Ronnekleiv-Kelly SM, Pawlik TM. Staging of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr 2017; 6: 35-43.
33. Enker WE, Dragacevic S. Multiple carcinomas of the large bowel: a natural experiment in etiology and pathogenesis. Ann Surg 1978; 187: 8-11.
34. Bae JM, Kim JH, Cho NY, Kim TY, Kang GH. Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location. Br J Cancer 2013; 109: 1004-12.
35. Oh HJ, Bae JM, Wen XY, Cho NY, Kim JH, Kang GH. Overexpression of POSTN in tumor stroma is a poor prognostic indicator of colorectal cancer. J Pathol Transl Med 2017; 51: 306-13.
36. Bae JM, Kim JH, Kang GH. Molecular subtypes of colorectal cancer and their clinicopathologic features, with an emphasis on the serrated neoplasia pathway. Arch Pathol Lab Med 2016; 140: 406-12.